Jared Gollob's Securities Transactions in Kymera Therapeutics, Inc.

Jared Gollob, an officer of Kymera Therapeutics, Inc., has filed a Form 144 notice detailing his securities transactions. The filing indicates that Gollob plans to sell 59,576 shares of common stock acquired through the exercise of stock options and the vesting of restricted stock units. The securities were acquired between March 1, 2023, and October 15, 2025. The aggregate market value of the securities to be sold is approximately $3,470,897.76. Additionally, Gollob sold 3,114 shares of common stock on October 13, 2025, generating gross proceeds of $186,840.00. The transactions are part of a 10b5-1 trading plan adopted on June 2, 2025. The filing highlights Gollob's ongoing transactions in Kymera Therapeutics' securities and provides transparency into his financial dealings with the company.